# Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

> **NCT07180745** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Badr University** · enrollment: 400 (estimated)

## Conditions studied

- Non-alcoholic Fatty Liver Disease NAFLD
- Non-alcoholic Steatohepatitis NASH

## Interventions

- **DRUG:** Pioglitazone (PIO)
- **DRUG:** Empagliflozin
- **DRUG:** Statin (Atorvastatin)
- **DRUG:** Empagliflozin plus Statin (Atorvastatin)
- **DRUG:** Pioglitazone plus Atorvastatin

## Key facts

- **NCT ID:** NCT07180745
- **Lead sponsor:** Badr University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07180745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07180745, "Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07180745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*